

# Clifton Bingham

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4670782/publications.pdf>

Version: 2024-02-01

160  
papers

18,791  
citations

53939

47  
h-index

16791

127  
g-index

169  
all docs

169  
docs citations

169  
times ranked

22527  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying Minimal and Meaningful Change in a Patient-Reported Outcomes Measurement Information System for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives. <i>Arthritis Care and Research</i> , 2022, 74, 588-597.	1.5	17
2	Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases. <i>Clinical Infectious Diseases</i> , 2022, 74, 427-436.	2.9	15
3	Fibromyalgias and glucocorticoid persistence among patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 1556-1562.	0.9	10
4	Patients with checkpoint inhibitor-induced inflammatory arthritis do not become seropositive for anti-cyclic citrullinated peptide when followed over time. <i>ACR Open Rheumatology</i> , 2022, 4, 83-84.	0.9	5
5	The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies. <i>Arthritis Research and Therapy</i> , 2022, 24, 11.	1.6	6
6	Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials. <i>Rheumatology and Therapy</i> , 2022, 9, 541-553.	1.1	3
7	Statin use and MRI subchondral bone marrow lesion worsening in generalized osteoarthritis: longitudinal analysis from Osteoarthritis Initiative data. <i>European Radiology</i> , 2022, 32, 3944-3953.	2.3	6
8	PROMIS Provides a Broader Overview of Health-related Quality of Life Than the ESSPRI in Evaluation of Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2022, , jrheum.210633.	1.0	0
9	The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. <i>Arthritis Research and Therapy</i> , 2022, 24, 83.	1.6	4
10	292 Fibromyalgias and Glucocorticoid Persistence Among Patients with Rheumatoid Arthritis. <i>Journal of Clinical and Translational Science</i> , 2022, 6, 51-51.	0.3	0
11	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153
12	Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials. <i>Arthritis Care and Research</i> , 2021, 73, 481-488.	1.5	4
13	Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021, 73, 471-480.	1.5	12
14	Spectrum and impact of checkpoint inhibitor-induced irAEs. <i>Nature Reviews Rheumatology</i> , 2021, 17, 69-70.	3.5	8
15	Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications. <i>Arthritis and Rheumatology</i> , 2021, 73, 553-565.	2.9	21
16	The Relationship Between Autonomic Dysfunction of the Gastrointestinal Tract and Emotional Distress in Patients With Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 11-17.	0.5	7
17	Patients and clinicians define symptom levels and meaningful change for PROMIS pain interference and fatigue in RA using bookmarking. <i>Rheumatology</i> , 2021, 60, 4306-4314.	0.9	13
18	Autoantibodies targeting telomere-associated proteins in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 912-919.	0.5	19

#	ARTICLE	IF	CITATIONS
19	Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. <i>ACR Open Rheumatology</i> , 2021, 3, 173-184.	0.9	88
20	A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2676-TPS2676.	0.8	4
21	OMERACT 2020: A virtual (R)evolution. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 588-592.	1.6	0
22	The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1320-1330.	1.6	25
23	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1113-1116.	1.6	4
24	Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity. <i>PLoS ONE</i> , 2021, 16, e0244187.	1.1	16
25	Feasibility and acceptability of using a meditation app in adults with rheumatic disease. <i>Explore: the Journal of Science and Healing</i> , 2021, , .	0.4	0
26	Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change. <i>Journal of Rheumatology</i> , 2020, 47, 333-340.	1.0	5
27	Association of Pain Centralization and Patient-Reported Pain in Active Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 1122-1129.	1.5	27
28	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 809-819.	1.0	16
29	Patient-reported outcomes in RA care improve patient communication, decision-making, satisfaction and confidence: qualitative results. <i>Rheumatology</i> , 2020, 59, 1662-1670.	0.9	42
30	Successful Methotrexate Treatment of Chronic Chikungunya Arthritis. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 119-124.	0.5	15
31	Association of Dysregulated Central Pain Processing and Response to Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 2017-2024.	2.9	17
32	Evaluation of Musculoskeletal and Pulmonary Bacterial Infections With [ <sup>124</sup> I]FIAU PET/CT. <i>Molecular Imaging</i> , 2020, 19, 153601212093687.	0.7	11
33	Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps. <i>BMC Rheumatology</i> , 2020, 4, 32.	0.6	18
34	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 453-459.	0.5	43
35	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020, 47, 796-808.	1.0	3
36	Assessing the content validity of patient-reported outcome measures in adult myositis: A report from the OMERACT myositis working group. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 943-948.	1.6	6

#	ARTICLE	IF	CITATIONS
37	Response to: "Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation" by Braaten et al: another point of view™ by Cappelli et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2019-216892.	0.5	1
38	Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis. Immunological Reviews, 2020, 294, 106-123.	2.8	24
39	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Annals of the Rheumatic Diseases, 2020, 79, 332-338.	0.5	140
40	IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis. Journal of Clinical Investigation, 2020, 130, 5493-5507.	3.9	119
41	A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).. Journal of Clinical Oncology, 2020, 38, TPS3158-TPS3158.	0.8	2
42	Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.5	3
43	Anxiety impacts rheumatoid arthritis symptoms and health-related quality of life even at low levels. Clinical and Experimental Rheumatology, 2020, 38, 1176-1181.	0.4	1
44	Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug. Arthritis Care and Research, 2019, 71, 521-529.	1.5	24
45	Sonographic Findings in Inflammatory Arthritis Secondary to Immune Checkpoint Inhibition: A Case Series. ACR Open Rheumatology, 2019, 1, 303-307.	0.9	30
46	PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis. Journal of Patient-Reported Outcomes, 2019, 3, 14.	0.9	33
47	Statin Use and Knee Osteoarthritis Outcome Measures according to the Presence of Heberden Nodes: Results from the Osteoarthritis Initiative. Radiology, 2019, 293, 396-404.	3.6	33
48	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1028-1035.	1.0	61
49	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. Journal of Rheumatology, 2019, 46, 1053-1058.	1.0	8
50	Delphi panelists for a core outcome set project suggested both new and existing dissemination strategies that were feasibly implemented by a research infrastructure project. Journal of Clinical Epidemiology, 2019, 114, 104-107.	2.4	12
51	Soluble Markers of Antibody Secreting Cell Function as Predictors of Infection Risk in Rheumatoid Arthritis. Journal of Immunology Research, 2019, 2019, 1-10.	0.9	9
52	Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Research and Therapy, 2019, 21, 102.	1.6	43
53	Advancing Stiffness Measurement in Rheumatic Disease: Report from the Stiffness Special Interest Group at OMERACT 2018. Journal of Rheumatology, 2019, 46, 1374-1378.	1.0	6
54	Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation. Trials, 2019, 20, 182.	0.7	31

#	ARTICLE	IF	CITATIONS
55	Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion. <i>Journal of Rheumatology</i> , 2019, 46, 1168-1172.	1.0	8
56	OMERACT 2018 Modified Patient-reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies. <i>Journal of Rheumatology</i> , 2019, 46, 1351-1354.	1.0	23
57	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. <i>Journal of Rheumatology</i> , 2019, 46, 1021-1027.	1.0	97
58	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1014-1020.	1.0	65
59	Sonographic findings from inflammatory arthritis due to antisynthetase syndrome. <i>Clinical Rheumatology</i> , 2019, 38, 1477-1483.	1.0	8
60	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. <i>Journal of Rheumatology</i> , 2019, 46, 1006-1013.	1.0	34
61	Patient-Reported Outcomes in Adult Idiopathic Inflammatory Myopathies. <i>Current Rheumatology Reports</i> , 2019, 21, 62.	2.1	11
62	Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study. <i>Journal of Rheumatology</i> , 2019, 46, 106-111.	1.0	25
63	Pain and Catastrophizing in Patients With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 232-236.	0.5	8
64	Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. <i>Rheumatology</i> , 2019, 58, 476-480.	0.9	77
65	A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 712-720.	2.3	71
66	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 114-122.	0.4	19
67	Phenotypic characterization of patients with rheumatologic manifestations of common variable immunodeficiency. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 318-326.	1.6	26
68	Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 94-106.	3.5	99
69	Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events. <i>Rheumatology</i> , 2018, 57, 760-762.	0.9	25
70	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 553-557.	1.6	119
71	Towards improving measurement of stiffness in rheumatology. <i>Rheumatology</i> , 2018, 57, 206-208.	0.9	0
72	Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-sectional Study. <i>Arthritis Care and Research</i> , 2018, 70, 197-204.	1.5	65

#	ARTICLE	IF	CITATIONS
73	Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 141-148.	0.5	13
74	Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 2696.	2.2	34
75	Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. , 2018, 6, 104.		55
76	Systematic Review and Meta-analysis: Mindfulness-Based Interventions for Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018, 20, 75.	2.1	39
77	Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis. <i>Quality of Life Research</i> , 2018, 27, 2443-2451.	1.5	17
78	A survey of Delphi panelists after core outcome set development revealed positive feedback and methods to facilitate panel member participation. <i>Journal of Clinical Epidemiology</i> , 2018, 102, 99-106.	2.4	39
79	Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 59.	1.6	19
80	A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6538-6538.	0.8	9
81	Pattern of muscle involvement in inclusion body myositis: a sonographic study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 996-1002.	0.4	13
82	Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases. <i>Arthritis Care and Research</i> , 2017, 69, 449-452.	1.5	15
83	Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. <i>Lancet, The</i> , 2017, 389, 1206-1217.	6.3	94
84	Montreal Accord on Patient-Reported Outcomes (PROs) use series – Paper 3: patient-reported outcomes can facilitate shared decision-making and guide self-management. <i>Journal of Clinical Epidemiology</i> , 2017, 89, 125-135.	2.4	79
85	Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 165-169.	1.6	10
86	Montreal Accord on Patient-Reported Outcomes (PROs) use series – Paper 8: patient-reported outcomes in electronic health records can inform clinical and policy decisions. <i>Journal of Clinical Epidemiology</i> , 2017, 89, 160-167.	2.4	26
87	Montreal Accord on Patient-Reported Outcomes (PROs) use series – Paper 4: patient-reported outcomes can inform clinical decision making in chronic care. <i>Journal of Clinical Epidemiology</i> , 2017, 89, 136-141.	2.4	57
88	Core Outcome Measures for Clinical Research in Acute Respiratory Failure Survivors. An International Modified Delphi Consensus Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1122-1130.	2.5	273
89	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , 2017, 22, 627-630.	1.9	74
90	Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. <i>Immunotherapy</i> , 2017, 9, 5-8.	1.0	20

#	ARTICLE	IF	CITATIONS
91	Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest Group. <i>Journal of Rheumatology</i> , 2017, 44, 1904-1910.	1.0	11
92	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 43-50.	0.5	317
93	Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. <i>Arthritis Care and Research</i> , 2017, 69, 1751-1763.	1.5	292
94	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1884-1888.	1.0	11
95	Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. <i>Journal of Rheumatology</i> , 2017, 44, 1536-1543.	1.0	25
96	Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study. <i>Journal of Rheumatology</i> , 2017, 44, 1683-1687.	1.0	21
97	Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. <i>Journal of Rheumatology</i> , 2017, 44, 1551-1559.	1.0	27
98	Proteolysis by Granzyme B Enhances Presentation of Autoantigenic Peptidylarginine Deiminase 4 Epitopes in Rheumatoid Arthritis. <i>Journal of Proteome Research</i> , 2017, 16, 355-365.	1.8	25
99	Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). <i>Patient</i> , 2017, 10, 141-152.	1.1	41
100	Immune-Related Adverse Effects of Cancer Immunotherapy" Implications for Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 65-78.	0.8	101
101	Spontaneous Secretion of the Citrullination Enzyme PAD2 and Cell Surface Exposure of PAD4 by Neutrophils. <i>Frontiers in Immunology</i> , 2017, 8, 1200.	2.2	82
102	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. , 2017, 5, 95.		1,460
103	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. <i>RMD Open</i> , 2016, 2, e000217.	1.8	35
104	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. <i>RMD Open</i> , 2016, 2, e000225.	1.8	54
105	The Reporting of Patient-reported Outcomes in Studies of Patients with Rheumatoid Arthritis: A Systematic Review of 250 Articles. <i>Journal of Rheumatology</i> , 2016, 43, 1300-1305.	1.0	41
106	Measuring transaminases in patients with rheumatoid arthritis on weekly methotrexate: does timing of blood testing matter?. <i>Clinical Rheumatology</i> , 2016, 35, 3053-3056.	1.0	1
107	Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. <i>RMD Open</i> , 2016, 2, e000321.	1.8	37
108	Using patient-reported outcomes and PROMIS in research and clinical applications: experiences from the PCORI pilot projects. <i>Quality of Life Research</i> , 2016, 25, 2109-2116.	1.5	51



#	ARTICLE	IF	CITATIONS
109	Increased pretreatment serum IFN- $\gamma$ ratio predicts non-response to tumour necrosis factor $\gamma$ inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1757-1762.	0.5	59
110	The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 687-695.	0.5	166
111	Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. <i>Journal of Rheumatology</i> , 2016, 43, 187-193.	1.0	46
112	Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week 112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1627-1636.	1.5	13
113	Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary. <i>Journal of Rheumatology</i> , 2015, 42, 2185-2189.	1.0	40
114	BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 347.	1.6	6
115	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. <i>Arthritis Research and Therapy</i> , 2015, 17, 343.	1.6	13
116	Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2015, 67, 1345-1353.	1.5	72
117	Patients' Experience of Myositis and Further Validation of a Myositis-specific Patient Reported Outcome Measure – Establishing Core Domains and Expanding Patient Input on Clinical Assessment in Myositis. Report from OMERACT 12. <i>Journal of Rheumatology</i> , 2015, 42, 2492-2495.	1.0	26
118	Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1762-1766.	1.5	11
119	Ultrasound assessment of response to intra-articular therapy in osteoarthritis of the knee. <i>Rheumatology</i> , 2015, 54, 1385-1391.	0.9	27
120	Citrullination of myofilament proteins in heart failure. <i>Cardiovascular Research</i> , 2015, 108, 232-242.	1.8	64
121	PPAD is not targeted as a citrullinated protein in rheumatoid arthritis, but remains a candidate for inducing autoimmunity. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e8-e8.	0.5	10
122	Yoga in Sedentary Adults with Arthritis: Effects of a Randomized Controlled Pragmatic Trial. <i>Journal of Rheumatology</i> , 2015, 42, 1194-1202.	1.0	66
123	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1567-1570.	0.5	31
124	Patient Reported Outcomes in Rheumatoid Arthritis Clinical Trials. <i>Current Rheumatology Reports</i> , 2015, 17, 28.	2.1	60
125	Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 818-822.	0.5	92
126	Rituximab-induced serum sickness: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 334-340.	1.6	88



#	ARTICLE	IF	CITATIONS
127	Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda. <i>Journal of Rheumatology</i> , 2015, 42, 1934-1942.	1.0	7
128	Defining the role of <i>Porphyromonas gingivalis</i> peptidylarginine deiminase (PPAD) in rheumatoid arthritis through the study of PPAD biology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2054-2061.	0.5	88
129	Reliability and Validity of Selected PROMIS Measures in People with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0138543.	1.1	164
130	Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 893-904.	1.4	12
131	Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2152-2159.	0.5	29
132	The Effect of Intravenous Golimumab on Health-related Quality of Life in Rheumatoid Arthritis: 24-week Results of the Phase III GO-FURTHER Trial. <i>Journal of Rheumatology</i> , 2014, 41, 1067-1076.	1.0	14
133	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 745-753.	2.4	625
134	Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: Expanding the spectrum of neurological disease associated with TNF-inhibitors. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 638-647.	1.6	31
135	Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1781-1787.	0.5	21
136	Cervical spine involvement early in the course of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 738-744.	1.6	37
137	Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop. <i>Journal of Rheumatology</i> , 2014, 41, 799-809.	1.0	65
138	Yoga in Rheumatic Diseases. <i>Current Rheumatology Reports</i> , 2013, 15, 387.	2.1	21
139	Peripheral quantitative CT (pQCT) using a dedicated extremity cone-beam CT scanner. <i>Proceedings of SPIE</i> , 2013, 8672, 867203.	0.8	16
140	Periodontal disease and rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 345-353.	2.0	133
141	Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 381-389.	0.5	90
142	FRI0521: A framework and process to develop core outcome measurement sets for clinical trials in rheumatology: omeract filter 2.0. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A550.3-A551.	0.5	0
143	Evaluating Osteoarthritic Chondrocytes through a Novel 3-Dimensional <i>In Vitro</i> System for Cartilage Tissue Engineering and Regeneration. <i>Cartilage</i> , 2012, 3, 128-140.	1.4	6
144	Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1855-1860.	0.5	131

#	ARTICLE	IF	CITATIONS
145	The importance of patient participation in measuring rheumatoid arthritis flares. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1107-1109.	0.5	25
146	'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count--an international patient perspective on flare where medical help is sought. <i>Rheumatology</i> , 2012, 51, 69-76.	0.9	121
147	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012, 51, 2204-2214.	0.9	115
148	Matrix metalloproteinases and inhibitors in cartilage tissue engineering. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2012, 6, 144-154.	1.3	12
149	Predictors of Response to Cyclo-Oxygenase-2 Inhibitors in Osteoarthritis: Pooled Results from Two Identical Trials Comparing Etoricoxib, Celecoxib, and Placebo. <i>Pain Medicine</i> , 2011, 12, 352-361.	0.9	11
150	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
151	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.5	2,994
152	Developing a Standardized Definition for Disease "Flare" in Rheumatoid Arthritis (OMERACT 9 Special) <i>Tj ETQq000 rgBT /Overlock</i>	1.0	108
153	Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo. <i>Rheumatology</i> , 2009, 48, 1122-1127.	0.9	27
154	Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1248-1256.	6.7	115
155	Immunomodulatory approaches to the management of chronic urticaria: An immune-mediated inflammatory disease. <i>Current Allergy and Asthma Reports</i> , 2008, 8, 277-287.	2.4	15
156	Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2008, 16, 1289-1293.	0.6	23
157	Response to Dr Gotzche and Dr Bjarnason. <i>Rheumatology</i> , 2007, 46, 1624-1625.	0.9	0
158	Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2006, 55, 325-332.	6.7	414
159	Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. <i>Arthritis and Rheumatism</i> , 2006, 55, 543-550.	6.7	7
160	Phospholipase A2 Enzymes in Eicosanoid Generation. <i>Proceedings of the Association of American Physicians</i> , 1999, 111, 516-524.	2.1	61